Benzinga | Jul 21, 2020 07:33AM EDT

Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity Of WP1122 In Coronavirus

HOUSTON, July 21, 2020 /PRNewswire/ --Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a second round of independent laboratory testing has confirmed the antiviral activity of WP1122 against coronavirus.